Rosetta Genomics, Ltd. (NASDAQ:
ROSG) leverages an integrative research platform to develop and commercialize a
full range of microRNA-based molecular diagnostics and address critical needs
in cancer and other disease areas. Building on its proprietary platform
technologies and a strong IP portfolio, the company is working to solve unmet
medical needs and improve the lives of patients through a proven combination of
diagnostic expertise and therapeutic innovations.
The company’s current product
pipeline includes an assortment of unique diagnostic tests for a collection of
medical conditions – including thyroid neoplasia, heart failure, kidney
rejection and Alzheimer’s disease. In recent months, Rosetta has worked to
build on this pipeline and expand its presence in the industry, most notably
through the acquisition of PersonalizeDx in April. PersonalizeDx is a rapidly
growing molecular diagnostics and services company serving community-based
pathologists, urologists, oncologists and other reference laboratories across
the United States.
“The acquisition of
PersonalizeDx will have wide-ranging, positive financial, commercial,
operational and pipeline impact on Rosetta Genomics, and brings with it
exceptional talent to complement the industry-leading team at Rosetta
Genomics,” stated Kenneth A. Berlin, president and chief executive officer of
Rosetta, in a recent news release. “In joining forces with PersonalizeDx,
Rosetta Genomics will gain critically important commercial and revenue scale in
the marketplace for oncology diagnostics.”
In May, Rosetta built on the
momentum gained from its acquisition by releasing OncoGxOne™, the company’s
next-generation sequencing panel that detects a vast number of genetic
alterations implicated in cancer to provide clear, concise and actionable
clinical recommendations from a single, comprehensive test. Moving forward,
OncoGxOne™ will compete with currently available genomic profiling offerings
through next-generation sequencing platforms that can identify potentially
actionable cancer-driving mutations, which can be targeted by specific
therapies.
“We look forward to a successful
commercial launch for OncoGxOne™ with our recently-expanded sales force and
expect that over time it will become an important contributor to our revenues,”
concluded Berlin.
Rosetta’s recent efforts have
strategically positioned the company to realize significant increases in
revenue in the coming years. Based on PersonalizeDx’s 2014 revenue, which was
$6.9 million, the company has modified its financial model, leading to forecast
revenue of $18.5 million in 2016. For prospective investors, this potential
growth could provide the opportunity for significant returns in the future.
For more information, visit
www.rosettagenomics.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
